Delivery system for budesonide based on lipid-DNA.

Area of Science:

• Biomaterials Science
• Drug Delivery Systems
• Nanotechnology

Background:

• Budesonide, a potent anti-inflammatory glucocorticoid, faces challenges due to its hydrophobicity, limiting its therapeutic efficacy.
• Current formulations of budesonide for asthma, inflammatory bowel disease, and rheumatoid arthritis may cause adverse effects.
• Developing advanced drug delivery systems is crucial for enhancing budesonide's bioavailability and reducing side effects.

Purpose of the Study:

• To develop a novel micellar drug delivery system for budesonide using lipid-DNA (UU11mer).
• To enhance budesonide's water solubility and loading capacity.
• To evaluate the anti-inflammatory activity of budesonide delivered via the lipid-DNA system.

Main Methods:

• Synthesis and characterization of lipid-DNAA (UU11mer) micelles.
• Incorporation of hydrophobic budesonide into the lipid-DNA micelles.
• Assessment of budesonide loading capacity and water solubility.
• In vitro evaluation of anti-inflammatory activity by measuring interleukin-8 (IL-8) release inhibition.

Main Results:

• The lipid-DNAA (UU11mer) system effectively rendered hydrophobic budesonide water-soluble.
• High loading capacity (LC) was achieved for budesonide within the micelles.
• The budesonide-loaded micelles demonstrated retained anti-inflammatory activity, evidenced by the inhibition of IL-8 release in cell-based assays.

Conclusions:

• A novel lipid-DNA micellar system offers an effective strategy for formulating and administering budesonide.
• This approach significantly improves budesonide's water solubility and maintains its bioavailability.
• The non-invasive administration of budesonide via this system holds promise for treating inflammatory conditions.